Companies / PIQ

PROTEOMICS INTERNATIONAL LABORATORIES LTD

ASX:PIQPharmaceuticals, Biotechnology & Life Sciences
165.4M shares on issueASX (delayed) · as of 28 July 2026$0.16price · delayed$25.6Mmarket cap · indicative
C
Dilution grade

Runway under 2 quarters; share count grew 26% in 24 months; 1 cash raise in 24 months

Cash runway1.4 quarters of funding
Share-count growth (24m)26.2%
Raise cadence (24m)1 cash raise
Options & rights overhang12.8% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

PROTEOMICS INTERNATIONAL LABORATORIES LTD's ordinary share count grew 26.2% between July 2024 and July 2026, to 165M shares. The company raised capital once in the 24‑month window for total disclosed proceeds of A$12.0M, via a raise in April 2025 that produced A$12.0M. Options and rights on issue could convert into 21M new shares, equal to 12.8% of the current share count, with 0% currently in the money and the nearest expiry in November 2026. At the June 2026 quarter the company reported A$2.9M in available cash, representing about 1.4 quarters of cover. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
12.8%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
1.4 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 165.4M per ASX (delayed) (28 July 2026).
138.2M148.2M158.2MDec 24Sept 25July 26Cash raise · 15 Apr 2025

Cash runway

1.4 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$2.9M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
12 July 20262A · quoted issuePIQ : ORDINARY FULLY PAID165.4MAppendix 2A
6 July 20263H · cancellationPIQ : ORDINARY FULLY PAID165.2MAppendix 3H
2 June 20262A · quoted issuePIQ: ORDINARY FULLY PAID165.2MAppendix 2A
1 Feb 20262A · quoted issuePIQ : ORDINARY FULLY PAID165.2MAppendix 2A
21 Jan 20262A · quoted issuePIQ : ORDINARY FULLY PAID165.1MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 0 in the last 12 months

$12.0M
Capital raise
15 Apr 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

12.8%
Total overhang · of current shares
0.0%
In the money · at current price
21.1M
Potential new shares
Nov 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
26 Nov 2025Aaron BrinkworthOther135k135k—3Y notice
26 Nov 2025Vicki RobinsonOther—250k—3Y notice
25 Nov 2025Neville GardinerSell199k250k—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

26 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
22 July 2026Webinar Presentation - Healius distribution agreement
21 July 2026$PProteomics signs national distribution deal with Healius
12 July 2026Application for quotation of securities - PIQ
8 July 2026$PUS patent secured for PromarkerEndo
6 July 2026Notification of cessation of securities - PIQ
3 July 2026$PResponse to ASX Price Query
2 July 2026Change of Registered Office Address
2 June 2026Application for Quotation of Securities - PIQ
7 May 2026$PResponse to ASX Price Query
1 May 2026Notification of Expiry of Listed Options - PIQO
27 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
27 Apr 2026$PProteomics Strategic Plan
17 Apr 2026Final Director's Interest Notice
16 Apr 2026$PRestructure, Executive Appointment and Board Update
24 Feb 2026$PAppendix 4D and Interim Financial Report
23 Feb 2026Final Director's Interest Notice
4 Feb 2026Resignation of Joint Company Secretary
1 Feb 2026Application for quotation of securities - PIQ
29 Jan 2026$PQuarterly Activities/Appendix 4C Cash Flow Report

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.